Publications by authors named "A Asagi"
Background: S-1 monotherapy had previously been widely used as a second-line treatment for pancreatic cancer (PC) after gemcitabine-based chemotherapy mainly in Japan. Based on the results of the NAPOLI-1 trial, the recommended second-line therapy is now liposomal irinotecan plus fluorouracil/folinic acid (nal-IRI + 5-FU/LV). However, there have been no studies comparing nal-IRI + 5-FU/LV therapy with S-1 monotherapy.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on using circulating tumor DNA (ctDNA) analysis to identify homologous recombination deficiency (HRD) and BRCA1/2 and ATM mutations in patients with advanced pancreatic cancer (APC).
- Out of 702 APC patients analyzed, 4.8% had BRCA1/2 mutations and 4.4% had ATM mutations, with those having BRCA mutations showing significantly better response rates to platinum-based chemotherapy compared to those without.
- ctDNA profiling is suggested as a valuable, non-invasive method for assessing mutation status and selecting appropriate treatments in advanced pancreatic cancer, offering a practical approach to HRD screening.
Article Synopsis
- Recent advancements in treatments for hepatocellular carcinoma (HCC) have improved patient survival, but these therapies are expensive, creating a financial burden on patients and society.
- A study analyzed first-line systemic treatments for advanced HCC in Japan, focusing on the number of patients receiving different treatments and their associated monthly costs from July 2021 to June 2022.
- The study found that 82.2% of patients received high-cost regimens, with atezolizumab plus bevacizumab being the most common and expensive treatment at 1,176,284 JPY per month.
Adrenal leiomyomas are rare and often reported as Epstein-Barr virus (EBV)-associated smooth muscle tumor (SMT) in association with EBV infection in immunocompromised patients. We experienced a case of right adrenal leiomyoma that was incidentally found in a man in his 70s. Computed Tomography (CT) showed a well-circumscribed mass of 3.
View Article and Find Full Text PDFArticle Synopsis
- Zinc deficiency is a significant issue for cancer patients undergoing long-term chemotherapy, but its effects on symptoms like skin rash, taste changes, and oral issues need more research.
- A study analyzed gastric and colorectal cancer patients receiving standard chemotherapy, finding that 38% had zinc deficiency before treatment and that serum zinc levels dropped further for those initially non-deficient during treatment.
- The decline in zinc levels was linked to worsening symptoms such as taste changes and skin issues, suggesting that future research should explore the potential benefits of zinc supplementation for these patients.